BOSTON, Jan 25 (Reuters) - Biopharmaceutical company Zafgen's stock tumbled as much as 11.5 percent in early trading on Monday after hedge fund Kerrisdale Capital said it has a short bet on the stock, arguing that U.S. regulators will not approve the sale of its obesity drug.
